Concourse Financial Group Securities, Inc. Silence Therapeutics PLC Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$15.53 - $21.74 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$18.31 - $23.91 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$17.39 - $26.25 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$6.7 - $17.67 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$5.07 - $10.74 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$5.07 - $10.74 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$4.61 - $7.44 $0 - $0
Q1 2023 May 15, 2023	BUY	$6.2 - $15.61 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$9.69 - $17.09 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$2.65 - $29.85 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$7.99 - $19.5 $0 - $0
Q1 2022 May 09, 2022	BUY	$16.5 - $23.89 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$20.61 - $25.71 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$20.61 - $26.87 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$22.34 - $28.35 $0 - $0
Q1 2021 May 13, 2021	BUY	$21.8 - $28.01 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$15.0 - $22.0 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$17.31 - $19.5 $0 - $0

Others Institutions Holding SLN

# of Institutions

Shares Held

27.1M

Call Options Held

Put Options Held

Tcg Crossover Management, LLC Palo Alto, CA

3.3M
Shares

$59.5 Million
9.38% of portfolio
Artal Group S.A. Luxembourg, N4

2.78M
Shares

$50.2 Million
3.35% of portfolio
Lombard Odier Asset Management (Usa) Corp New York, NY

2.41M
Shares

$43.5 Million
3.46% of portfolio
Redmile Group, LLC San Francisco, CA

2.01M
Shares

$36.4 Million
2.5% of portfolio
Logos Global Management LP San Francisco, CA

1.48M
Shares

$26.7 Million
2.63% of portfolio

View Full List

About Silence Therapeutics plc

Ticker SLN
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,888,400
Market Cap $649M
Description
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...

More about SLN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account